HEALTH OF WOMAN. 2016.3(109):93–98; doi 10.15574/HW.2016.109.93 
 

Treatment of dishormonal dysplasia of mammary glands 
 

Reznichenko G. I., Reznichenko N. Yu., Potebnya V. Yu.

SI «Zaporozhzhia medical Academy of postgraduate education Ministry of health of Ukraine» 
 

The objective: to determine the effectiveness of Epigalin Breast in treatment of women with dishormonal dysplasia of mammary glands.

Patients and methods. We observed 67 women with dishormonal dysplasia of mammary glands aged 32–46 years who received complex therapy, which included sedatives, vitamins and Epigalin Breast additionally as well as 23 healthy not pregnant women.

Results. The use of Epigalin Breast leads to decrease in the secretion of prolactin, resulting in regression of pathological processes in mammary glands and disappearance of pain. Cyclic secretion of gonadotropic hormones and normal level of prolactin restores the second phase of menstrual cycle, normalizing the imbalance between the level of estradiol and progesterone, which positively affects the state of the mammary glands.

Conclusion. The results indicate high effectiveness and safety of Epigalin Breast and prove the need to recommend it for wide introduction and use in gynecological practice for treatment and preventive measures for women with dyshormonal breast dysplasia and hormone-dependent pathologies of the genitals caused by hyperestrogenic states.

Key words: dishormonal breast dysplasia, treatment, Epigalin Breast.

REFERENCES

1. Voloshyna NM, Pashchenko SM, Lutsenko NS, Reznichenko HI. 2010. Diahnostyka ta likuvannia dyshormonalnoi hiperplazii molochnoi zalozy (mastopatii). Metod. rek. Zaporizhzhia, «Prynt»:44.

2. Grischenko OV, Abdullaev RYa, Dolenko OV. 2009. Ultrazvukovaya diagnostika i kompleksnoe lechenie diffuznoy fibrozno-kistoznoy mastopatii u zhenschin reproduktivnogo vozrasta. Zdorove zhenschinyi 9(45):134–136.

3. Zulkarnaeva ET, Hakimova RH, Lapan EI. 2008. Indinol-3-karbinol v lechenii dobrokachestvennyih zabolevaniy molochnoy zhelezyi. Opuholi zhenskoy reproduktivnoy sistemyi 3:50–54.

4. Kiselev IV, Lyashenko AA. 2008. Indinol – regulyator proliferativnyih protsessov v organah reproduktivnoy sistemyi. M, ZAO «MiraksFarma»:48.

5. Kornatska AH, Dubenko OD. 2012. Fitoselektyvna terapiia u zhinok z bezplidnistiu ta dobroiakisnymy zakhvoriuvanniamy molochnykh zaloz na etapakh reabilitatsii reproduktyvnoi funktsii. Zdorove zhenshchynы 6(72):218–221.

6. Molochna zaloza: rak i predrakovi zakhvoriuvania. Pid red. Tarutynova VI. K, «Polihrafist». 2006:415.

7. Molochnyie zhelezyi i ginekologicheskie bolezni. Pod. red. VE Radzinskogo. M. 2010:304.

8. Mustafin ChK, Kuznetsova SV. 2009. Disgormonalnyie bolezni molochnoy zhelezyi. Klinicheskoe rukovodstvo. Pod red. Pinhosevicha EG. M:126.

9. Pashchenko SM, Reznichenko HI, Voloshyn MA. 2011. Diahnostyka ta likuvannia khvorykh na dyshormonalni hiperplazii molochnoi zalozy. Zaporizhzhia, Prosvita:152.

10. Rahimzhanova RI, Suleymenova EV, Mayer KM. 2007. Opyit primeneniya indinola pri lechenii razlichnyih form mastopatii v Kazahstane. Organizatsionnyie, meditsinskie i tehnicheskie aspektyi klinicheskoy mammologii. Mater. 5 Vseros. nauchno-prakt. konf. s mezhdunar. uchastiem. M:130–132.

11. Rozhkova NI, Meskih EV. 2007. Otsenka effektivnosti preparata indinol pri lechenii razlichnyih form mastopatii. Organizatsionnyie, meditsinskie i tehnicheskie aspektyi klinicheskoy mammologii. Mater. 5 Vseros. nauchno-prakt. konf. s mezhdunar. uchastiem. M:149–152.

12. Smolanka II. 2013. Lechenie fibrozno-kistoznoy bolezni – put profilaktiki raka molochnoy zhelezyi. Reproduktivnaya endokrinologiya 2(22):2309–4117.

13. Tatarchuk TF. 2011. Mastalhyia v voprosakh y otvetakh. Z turbotoiu pro zhinku 3:48–50.

14. Tatarchuk TF, Kalugina LV, Efimenko OA. 2012. Opyit lecheniya mastalgii u patsientok s disgormonalnyimi zabolevaniyami molochnoy zhelezyi. Reproduktivnaya endokrinologiya 3(5):63–69.

15. Tovstanovskaya VA, Vorobey-Vihovskaya VN, Saharova IA. 2010. Novoe slovo v negormonalnoy terapii fibrozno-kistoznoy mastopatii. Zdorove zhenschinyi 1(47):64–66.

16. Chayka VK, Sergeenko MYu, Lasachko SA. 2006. Molochnaya zheleza ot 0 do 18. Donetsk:120.

17. Endokrinnaya ginekologiya (klinicheskie ocherki). Chast 1. Pod red. TF Tatarchuk, YaP Solskiy. K, ZapovIt. 2003:303.

18. Chen C, Sakoda LC, Doherty Jennifer A. 2008, Dec. Fish Sherianne Genetic Variation in CYP19A1 and Risk of Breast Cancer and Fibrocystic Breast Conditions among Women in Shanghai, China. Cancer Epidemiol. Biomarkers Prev. 17:3457–3466.

19. Kushi Lawrence H, Byers T, Doyle C. 2006. American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention. Cancer J. Clin. 56:254–281. http://dx.doi.org/10.3322/canjclin.56.5.254

20. Plu-Bureau G, Lк MG, Sitruk-Ware R. 2006, June. Cyclical Mastalgia and Breast Cancer Risk: Results of A French Cohort Study. Cancer Epidemiology Biomarkers & Prevention. 15:1229–1231.

21. Poola Indira, Jessy A, Marshalleck Josephine J. 2008, February 15. Risk Assessment for Breast Cancer Development in Patients with Ductal Hyperplasias. Clinical Cancer Research 14:1274.

22. Rohan Thomas E, Negassa A, Rowan T. 2008. Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial. JNCI Journal of the National Cancer Institute 100(8):563–571. http://dx.doi.org/10.1093/jnci/djn075; PMid:18398105

23. Speirs V, Atkin SL. 1999. Production of VGEF and expression of the VEGF receptors Аде-1 and KDR in primary cultures of epithlial and stromal cells derived from breast tumors. Br J Cancer 80(5–6):898–903.